Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.42 |
| ▸ | REN | P00797 | 7/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 4/20 | 0.34 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12333816 | 0.85 | HTR2A (0.36) | HRH3RENCYP3A4BRD4ATAD2 | |
| SCHEMBL15037580 | 0.85 | BRD4 (0.43) | HRH3RENCYP3A4BRD4ATAD2 | |
| SCHEMBL15037979 | 0.85 | HRH3 (0.51) | HRH3RENCYP3A4BRD4ATAD2 | |
| SCHEMBL15037986 | 0.84 | HRH3 (0.56) | HRH3RENCYP3A4BRD4ATAD2 | |
| SCHEMBL13998593 | 0.84 | HRH3 (0.46) | HRH3RENCYP3A4BRD4ATAD2 | |
| SCHEMBL15037981 | 0.84 | HRH3 (0.42) | HRH3RENCYP3A4BRD4ATAD2 | |
| SCHEMBL15037983 | 0.83 | HRH3 (0.58) | HRH3REN | |
| Hydrochloric Acid SCHEMBL16267293 | 0.83 | KMT2A (0.43) | HRH3RENCYP3A4BRD4ATAD2 | |
| SCHEMBL15037711 | 0.81 | REN (0.38) | HRH3RENCYP3A4BRD4ATAD2 | |
| SCHEMBL15037714 | 0.81 | REN (0.37) | HRH3RENCYP3A4BRD4ATAD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9107848-B2 | Coupler with cationic 7-amino-1,2,3,4-tetrahydroquinoline structure, dyeing composition comprising same, processes and uses | L'OREAL (FR) | 2015-08-18 | — | — | US | disclosed |
| US-20140352713-A1 | COUPLER WITH CATIONIC 7-AMINO-1,2,3,4-TETRAHYDROQUINOLINE STRUCTURE, DYEING COMPOSITION COMPRISING SAME, PROCESSES AND USES | L'OREAL (FR) | 2014-12-04 | — | — | US | disclosed |
| WO-2013087931-A1 | COUPLER WITH CATIONIC 7-AMINO-1,2,3,4-TETRAHYDROQUINOLINE STRUCTURE, DYEING COMPOSITION COMPRISING SAME, PROCESSES AND USES | L'OREAL (FR) | 2013-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140352713-A1 | COUPLER WITH CATIONIC 7-AMINO-1,2,3,4-TETRAHYDROQUINOLINE STRUCTURE, DYEING COMPOSITION COMPRISING SAME, PROCESSES AND USES | KRT18, PRMT7, ARGLU1 | HRH3 29/4885REN 409/4885CYP3A4 2623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.